Hims & Hers Health, Inc. $HIMS Shares Sold by 111 Capital

111 Capital cut its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 32.5% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,481 shares of the company’s stock after selling 6,970 shares during the period. 111 Capital’s holdings in Hims & Hers Health were worth $722,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of HIMS. Nuveen LLC acquired a new stake in Hims & Hers Health in the 1st quarter worth approximately $58,403,000. Yong Rong HK Asset Management Ltd boosted its stake in Hims & Hers Health by 41.2% in the 1st quarter. Yong Rong HK Asset Management Ltd now owns 2,400,000 shares of the company’s stock worth $70,920,000 after purchasing an additional 700,100 shares in the last quarter. CloudAlpha Capital Management Limited Hong Kong acquired a new stake in Hims & Hers Health in the 1st quarter worth approximately $20,580,000. Jump Financial LLC lifted its stake in Hims & Hers Health by 633.2% during the 1st quarter. Jump Financial LLC now owns 725,445 shares of the company’s stock valued at $21,437,000 after acquiring an additional 626,496 shares during the period. Finally, Northern Trust Corp boosted its holdings in shares of Hims & Hers Health by 19.5% in the 1st quarter. Northern Trust Corp now owns 2,435,512 shares of the company’s stock valued at $71,969,000 after acquiring an additional 397,310 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Morgan Stanley reaffirmed an “equal weight” rating and issued a $40.00 price objective on shares of Hims & Hers Health in a report on Wednesday, June 11th. Needham & Company LLC reaffirmed a “hold” rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. UBS Group set a $30.00 price objective on shares of Hims & Hers Health in a report on Monday, June 23rd. Truist Financial dropped their price objective on shares of Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating on the stock in a report on Monday, August 18th. Finally, Citigroup reaffirmed a “sell” rating on shares of Hims & Hers Health in a report on Monday, June 23rd. Two analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Reduce” and a consensus price target of $38.92.

Hims & Hers Health Stock Performance

HIMS opened at $52.61 on Friday. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46. The firm has a fifty day moving average price of $51.47 and a 200 day moving average price of $47.25. Hims & Hers Health, Inc. has a 1 year low of $16.69 and a 1 year high of $72.98. The stock has a market cap of $11.89 billion, a P/E ratio of 65.77, a P/E/G ratio of 3.55 and a beta of 2.25.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The firm had revenue of $544.83 million during the quarter, compared to analyst estimates of $550.06 million. During the same quarter in the prior year, the firm earned $0.06 earnings per share. The business’s revenue for the quarter was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Activity at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 145,000 shares of the business’s stock in a transaction on Monday, September 15th. The shares were sold at an average price of $55.35, for a total value of $8,025,750.00. Following the completion of the transaction, the chief financial officer directly owned 128,984 shares in the company, valued at $7,139,264.40. The trade was a 52.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Patrick Harrison Carroll sold 60,000 shares of the business’s stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $53.58, for a total transaction of $3,214,800.00. Following the completion of the transaction, the insider owned 169,940 shares of the company’s stock, valued at approximately $9,105,385.20. This represents a 26.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,622,727 shares of company stock worth $83,566,691 in the last three months. Company insiders own 13.71% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.